.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,238,647

« Back to Dashboard

Details for Patent: 6,238,647

Title: Aerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane
Abstract:This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.
Inventor(s): Akehurst; Rachel Ann (Ware, GB), Taylor; Anthony James (Ware, GB), Wyatt; David Andrew (Ware, GB)
Assignee: Glaxo Group Limited (Greenford, GB)
Filing Date:Nov 02, 1999
Application Number:09/431,872
Claims:1. A canister suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapor pressure of the propellant which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which consists essentially of particulate medicament which is salmeterol xinafoate and an anticholinergic medicament which is selected from the group consisting of ipratropium, atropine, oxitropium and salts thereof, in combination and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w of surfactant based on the weight of the medicament, the particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

2. A canister suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapor pressure of the propellant which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which consists of particulate medicament which is salmeterol xinafoate and an anticholinergic medicament which is selected from the group consisting of ipratropium, atropine, oxitropium and salts thereof, in combination and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

3. A canister as claimed in claim 2 wherein the anticholinergic medicament is ipratropium or a salt thereof.

4. A canister as claimed in claim 2 wherein the anticholinergic medicament is ipratropium or a salt thereof.

5. A canister according to claim 1 wherein the medicament is present in an amount of 0.1 to 1% w/w based on the weight of formulation.

6. A canister according to claim 2 wherein the medicament is present in an amount of 0.1 to 1% w/w based on the weight of formulation.

7. A canister according to claim 1 wherein the container is a metal can.

8. A canister according to claim 2 wherein the container is a metal can.

9. A canister according to claim 7 wherein the container is an aluminum can which is optionally anodised, lacquer coated and/or plastics coated.

10. A canister according to claim 8 wherein the container is an aluminum can which is optionally anodised, lacquer coated and/or plastics coated.

11. A canister according to claim 9 wherein the container is an aluminum can which is plastics coated.

12. A canister according to claim 10 wherein the container is an aluminum can which is plastics coated.

13. A canister suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapour pressure of the propellant which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which consists essentially of particulate medicament which is salmeterol or a physiologically acceptable salt or solvate thereof and an anticholinergic medicament which is selected from the group consisting of ipratropium. atropine, oxitropium and salts thereof, in combination and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% of surfactant, the particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc